ALLFTD

Dr. Boxer leads the ALLFTD consortium together with Dr. Howard Rosen (UCSF) and Dr. Brad Boeve (Mayo Clinic). The ALLFTD consortium merges two previous research studies (ARTFL:  Advancing Research and Treatment for Frontotemporal Lobar Degeneration and LEFFTDS: Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects) and consists of 23 clinical sites that evaluate participants. ALLFTD studies both sporadic and genetic forms of frontotemporal lobar degeneration (FTLD), including behavioral variant FTD (bvFTD), primary progressive aphasia (PPA; both semantic and agrammatic variants), corticobasal syndrome (CBS/CBD), and progressive supranuclear palsy (PSP); genetic forms of FTLD may be due to mutations in several different genes, including C9orf72, MAPT, and GRN.  Additionally, ALLFTD enrolls healthy participants who have a strong family history of FTLD syndromes, with or without a known genetic basis. More information is available at allftd.org.